WFRF:(Vande Walle Johan)
Sökning: WFRF:(Vande Walle Johan) > An audit analysis o...
An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome
- Johnson, Sally (författare)
- Stojanovic, Jelena (författare)
- Ariceta, Gema (författare)
- visa fler...
- Bitzan, Martin (författare)
- Besbas, Nesrin (författare)
- Frieling, Michelle (författare)
- Landau, Daniel (författare)
- Langman, Craig (författare)
- Licht, Christoph (författare)
- Pecoraro, Carmine (författare)
- Riedl, Magdalena (författare)
- Siomou, Ekaterini (författare)
- van de Kar, Nicole (författare)
- Vande Walle, Johan (författare)
- Loirat, Chantal (författare)
- Taylor, C. Mark (författare)
- visa färre...
- (creator_code:org_t)
- 2014-05-11
- 2014
- Engelska.
- Ingår i: Pediatric Nephrology. - : Springer Science and Business Media LLC. - 1432-198X .- 0931-041X. ; 29:10, s. 1967-1978
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- In 2009, the European Paediatric Study Group for Haemolytic Uraemic Syndrome (HUS) published a clinical practice guideline for the investigation and initial therapy of diarrhea-negative HUS (now more widely referred to as atypical HUS, aHUS). The therapeutic component of the guideline (comprising early, high-volume plasmapheresis) was derived from anecdotal evidence and expert consensus, and the authors committed to auditing outcome. Questionnaires were distributed to pediatric nephrologists across Europe, North America, and the Middle East, who were asked to complete one questionnaire per patient episode of aHUS between July 1, 2009 and December 31, 2010. Comprehensive, anonymous demographic and clinical data were collected. Seventy-one children were reported with an episode of aHUS during the audit period. Six cases occurred on a background of influenza A H1N1 infection. Of 71 patients, 59 (83 %) received plasma therapy within the first 33 days, of whom ten received plasma infusion only. Complications of central venous catheters occurred in 16 out of 51 patients with a catheter in-situ (31 %). Median time to enter hematological remission was 11.5 days, and eight of 71 (11 %) patients did not enter hematological remission by day 33. Twelve patients (17 %) remained dialysis dependent at day 33. This audit provides a snapshot of the early outcome of a group of children with aHUS in the months prior to more widespread use of eculizumab.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Pediatrik (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Pediatrics (hsv//eng)
Nyckelord
- Atypical hemolytic-uremic syndrome
- Alternative complement pathway
- Plasmapheresis
- Complement dysregulation
- Chronic kidney disease
- Thrombotic microangiopathy
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta mer i SwePub
- Av författaren/redakt...
- Johnson, Sally
- Stojanovic, Jele ...
- Ariceta, Gema
- Bitzan, Martin
- Besbas, Nesrin
- Frieling, Michel ...
- visa fler...
- Karpman, Diana
- Landau, Daniel
- Langman, Craig
- Licht, Christoph
- Pecoraro, Carmin ...
- Riedl, Magdalena
- Siomou, Ekaterin ...
- van de Kar, Nico ...
- Vande Walle, Joh ...
- Loirat, Chantal
- Taylor, C. Mark
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Pediatrik
- Artiklar i publikationen
- Pediatric Nephro ...
- Av lärosätet
- Lunds universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
